Management of Non-Hodgkin’s Lymphomas: Conclusions of the Third Intercity Meeting, 1988

  • J. Estapé
  • L. Brandao
  • N. de Lena
  • J. Garcia-Conde
  • J. Gary Bobo
  • J. A. Gastaut
  • P. Mazza
  • E. Montserrat
Conference paper
Part of the ESO Intercity Report book series (ESO INTERCITY)

Abstract

A third Intercity Meeting under the auspices of the European School of Oncology was held in Barcelona on 27th May, 1988. The subject of the meeting was the current management of non-Hodgkin’s lymphoma (NHL) and the results of the discussion are reported in this paper.

Keywords

Toxicity Europe Lymphoma Oncol Resis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Portlock CS: “Good risk” non-Hodgkin’s lymphomas: approaches to management. Sem Hematol 1983 (20): 25–34Google Scholar
  2. 2.
    Kinsella TJ: Role of combined-modality therapy in the curative management of advanced-stage “favorable” non-Hodgkin’s lymphomas. Cancer Treat Rep 1982 (66):421–426PubMedGoogle Scholar
  3. 3.
    Montserrat E, Gardella S, Llebaria C, Rozman C: Deferral of initial therapy in advanced “favorable” lymphomas. In: Sotto JJ et al (eds) Non-Hodgkin’s Lymphomas: New Techniques and Treatments. Karger, Basle 1985 pp 215–220Google Scholar
  4. 4.
    De Vita VT Jr, Longo DL, Hubbard SM, Young RC, Chabner BA: The lymphomas: biologic implications of therapy and therapeutic implications of the new biology. In: Malignant Lymphoma. Williams & Wilkins, Baltimore 1987 pp 249–267Google Scholar
  5. 5.
    Giralt M, Montserrat E, Maldonado J et al: Terapéutica de los limfomas no hodgkinianos clínicamente agresivos en estadios III y IV con CHOP. Neoplasia 1986 (3):119–124Google Scholar
  6. 6.
    Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES and De Vita VT Jr: The treatment of indolent lymphomas: watchful and waiting vs aggressive combined modality treatment. Sem Hematol Vol 25, No 2, suppl 2 1988pp 11–16Google Scholar
  7. 7.
    Lee R, Cabanillas F, Bodey GP, Freireich EJ: A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. J Clin Oncol 1986 (4): 1455–1461PubMedGoogle Scholar
  8. 8.
    McLaughlin P, Fuller LM, Velasquez WS et al: Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 1987 (5):867–874PubMedGoogle Scholar
  9. 9.
    Miller ThP, Dana BW, Weick JK et al: Southwest Oncology Group Clinical Trials for intermediate and high grade non-Hodgkin’s lymphomas. Sem Hematol Vol 25 No 2 suppl 2 pp 1988 17–22Google Scholar
  10. 10.
    Programa para el estudio y el tratamiento de las hemopatias malignas (PETHEMA). Protocolo XXI, linfomas no Hodgkin, CHOP-ProMACE CytaBOMGoogle Scholar
  11. 11.
    Philip T, Armitage JO, Spitzer G et al: High-dose therapy and autologous bohe marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987 (316):1493–1498PubMedCrossRefGoogle Scholar
  12. 12.
    Takvorian T, Canellos GP, Ritz J et al: Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin’slymphoma with a poor prognosis. N Engl J Med 1987 (316):1499–1505PubMedCrossRefGoogle Scholar
  13. 13.
    Anderson JR, Wilson JF, Jenkin DT et al: Childhood non-Hodgkin’s lymphomas: results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) to a 10-drug regimen (LSA2 L2). N Engl J Med 1983 (308):559PubMedCrossRefGoogle Scholar
  14. 14.
    Duque-Hammershaimb L, Wollner N, Miller DR: LSA2-L2 protocol treatment of stage IV non-Hodgkin’s lymphoma in children with partial and extensive bone marrow involvement. Cancer 1983 (52):39PubMedCrossRefGoogle Scholar
  15. 15.
    Slater DE, Mertelsmann R, Koziner B et al: Lymphoblastic lymphoma in adults. J Clin Oncol 1986(4):57PubMedGoogle Scholar
  16. 16.
    Philip T, Armitage JO, Spitzer G et al: High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non-Hodgkin’s lymphoma. New Engl J Med 1987 (316):1493PubMedCrossRefGoogle Scholar
  17. 17.
    Nademanee AP, Foreman JJ, Schmidt GM et al: Allogenic bone marrow transplantation for high risk non-Hodgkin’s lymphoma during first complete remission. Blut 1987 (55):11PubMedCrossRefGoogle Scholar
  18. 18.
    Magrath I, Lee YJ, Anderson T et al: Prognostic factors in Burkitt’s lymphoma: importance of total tumor burden. Cancer 1980 (45):1507PubMedCrossRefGoogle Scholar
  19. 19.
    Ziegler JL: Burkitt’s lymphoma. New Engl J Med 1981 (305):735PubMedCrossRefGoogle Scholar
  20. 20.
    Coiffier B, Bosly A, Galligaris-Cappio F et al, European School of Oncology: Management of non-Hodgkin’s lymphomas: conclusions of the European School of Oncology meeting, 1986. Eur J Cancer Clin Oncol 1987 (23):1691 –1695PubMedCrossRefGoogle Scholar
  21. 21.
    Cabanillas F, Hagemeister FB, Riggs S et al: Results of iphosphamide-etoposide combinations for patients with recurrent or refractory aggressive lymphoma. In: Cavalli F, Bonadonna G, Rozencweig M (eds) Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. 1985 p 485Google Scholar
  22. 22.
    Lennert T, Mohori M, Stein H: The histopathology of malignant lymphoma. Br J Haematol 1975 (31 suppl):193–203CrossRefGoogle Scholar
  23. 23.
    Zinzani PL, Gherlinzoni F, Lauria F et al: Intensive chemotherapy regimen in high-grade non-Hodgkin’s lymphomas. Tumori 1987 (73):121–126PubMedGoogle Scholar
  24. 24.
    Tura S, Mazza P, Gherlinzoni F et al: High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin’s lymphomas. Scand J Haematol 1986 (37):347–352PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • J. Estapé
    • 1
  • L. Brandao
    • 2
  • N. de Lena
    • 3
  • J. Garcia-Conde
    • 4
  • J. Gary Bobo
    • 5
  • J. A. Gastaut
    • 6
  • P. Mazza
    • 7
  • E. Montserrat
    • 8
  1. 1.Oncology ServiceHospital ClinicBarcelonaSpain
  2. 2.Institute of OncologyCoimbraPortugal
  3. 3.Ospedale OncologicoBariItaly
  4. 4.Haemato-oncology ServiceHospital ClinicoValenciaSpain
  5. 5.Centre Paul LamarqueMontpellierFrance
  6. 6.Haematology ServiceInstitut J. Paoli -I. CalmettesMarseilleFrance
  7. 7.Haematology Institute S. and A. SeragnoliBolognaItaly
  8. 8.School of HaematologyHospital ClinicBarcelonaSpain

Personalised recommendations